Aspirin plus ticlopidine prevented experimental endocarditis due to Enterococcus faecalis and Streptococcus

Tiago Rafael Veloso1, Frank Oechslin1, Yok-Ai Que2

  • 1Department of Fundamental Microbiology, University of Lausanne, CH-1015 Lausanne, Switzerland.

Pathogens and Disease
|August 28, 2015
PubMed

Insights

Aspirin and ticlopidine significantly reduced infective endocarditis (IE) in rats caused by Enterococcus faecalis and Streptococcus gallolyticus. This combination therapy shows promise for preventing IE in high-risk individuals.

Area of Science:

  • Cardiovascular Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Infective endocarditis (IE) is a serious bloodstream infection often caused by bacteria like Enterococcus faecalis and Streptococcus gallolyticus.
  • Antibiotic prophylaxis is ineffective for preventing IE originating from low-level bacterial translocation.
  • Previous studies showed aspirin plus ticlopidine protected against IE caused by other bacteria.

Purpose of the Study:

  • To evaluate the efficacy of aspirin plus ticlopidine in preventing IE caused by Enterococcus faecalis and Streptococcus gallolyticus.
  • To determine if this combination therapy can reduce vegetation weight and mortality in a rat model.

Main Methods:

  • A rat model of infective endocarditis was used.
  • Rats were treated with aspirin plus ticlopidine.
  • Vegetation weight and survival rates were measured to assess treatment efficacy.

Main Results:

  • Aspirin plus ticlopidine significantly reduced vegetation weight in rats with IE.
  • The treatment protected 73% of rats from Enterococcus faecalis IE.
  • The treatment protected 64% of rats from Streptococcus gallolyticus IE.

Conclusions:

  • Aspirin plus ticlopidine demonstrates significant protective effects against IE caused by Enterococcus faecalis and Streptococcus gallolyticus.
  • These findings support the potential use of aspirin plus ticlopidine for the global prevention of IE in high-risk patient populations.

Related Concept Videos

Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
334
Endocarditis I: Introduction01:25

Endocarditis I: Introduction

Introduction:Endocarditis is the infection of the endocardium, the inner lining of the heart and its valves. When the heart muscle is involved, the condition is termed myocarditis, while an infection of the outer lining is called pericarditis. Infective endocarditis (IE) primarily affects the endocardium, where pathogens adhere to the valves or lining, forming vegetation that can lead to severe complications. Infective endocarditis occurs when microorganisms, usually bacteria from other body...
777
Endocarditis IV: Nursing Management01:29

Endocarditis IV: Nursing Management

Infective endocarditis (IE) is a chronic infection of the heart's endocardium, primarily affecting the heart valves. A detailed nursing assessment for a patient with IE involves collecting subjective and objective data to ensure an accurate diagnosis and timely intervention.Subjective DataThe nurse gathers information about the patient's symptoms and complaints during the subjective assessment. Patients with infective endocarditis often report non-specific symptoms that can mimic other...
582
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
804
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.1K